Welcome to our dedicated page for North Amern Platinum news (Ticker: NOAP), a resource for investors and traders seeking the latest updates and insights on North Amern Platinum stock.
The NOAP news page on Stock Titan focuses on coverage where Nordic Aqua Partners (NOAP) appears within the public disclosures of Israel Corporation Ltd. ("ILCO"). In ILCO's financial reporting, Nordic Aqua Partners is identified by the symbol NOAP and is included among ILCO's "Other" assets alongside its core holdings. As a result, news that discusses ILCO's portfolio composition, total assets, or changes in its holdings can provide indirect context for NOAP.
ILCO describes itself as a public investment company that owns and invests in companies with established managements and defined go-to markets. Within this framework, NOAP is mentioned as part of the group of equity positions that contribute to ILCO's reported asset base. News items that summarize ILCO's quarterly or annual results may reference Nordic Aqua Partners when listing the components of ILCO's portfolio.
On this page, readers can expect news that highlights how NOAP is presented in ILCO's asset tables and how it fits into the "Other" assets category together with ILCO's larger stakes in ICL Group and AKVA Group. Because the available information is centered on ILCO's perspective, the coverage here will reflect mentions of NOAP in that context rather than standalone corporate announcements from Nordic Aqua Partners.
For investors tracking NOAP through its connection to ILCO, this page can be used as a reference point to follow how Nordic Aqua Partners is described in ILCO's public communications about its investment portfolio and total assets.
Israel Corporation (TASE: ILCO) reported third quarter results for the period ended September 30, 2025. Key items: ILCO share in ICL profit $51m, Prodalim profit $1m, amortization and HQ costs of <$3m> each, and net profit to shareholders $46m.
Liquidity: ILCO reported financial liabilities $660m and investments in liquid assets $695m (including $8m pledged), leaving a $35m liquid-asset surplus and net cash $45m as of Sept 30, 2025 (up from $26m on June 30, 2025); this net cash reflects a $10m derivatives adjustment reducing economic liabilities.
Balance sheet: total assets include ICL market value $3,550m, Prodalim cost $118m, AKVA market value $62m, other $19m, giving total assets $3,749m and total assets, net $3,794m.
Summary not available.
Summary not available.